Direct Acting Antivirals for Decompensated Cirrhosis. Efficacy and Safety Are Now Established

Journal of Hepatology - Netherlands
doi 10.1016/j.jhep.2016.02.041
Full Text
Abstract

Available in full text

Categories
Hepatology
Date
Authors
Publisher

Elsevier BV

Related search

Editorial: Ribavirin Continues to Play a Role in Treatment With Direct-Acting Antivirals for Hepatitis C Virus-Infected Patients With Decompensated Cirrhosis

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2017English

Efficacy and Safety of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients Taking Proton Pump Inhibitors

Journal of Clinical and Translational Hepatology
2017English

Direct-Acting Antivirals and Recurrence of Hepatocellular Carcinoma

Liver Transplantation
HepatologyTransplantationSurgery
2017English

High Efficacy of Generic and Brand Direct Acting Antivirals in Treatment of Chronic Hepatitis C.

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2018English

Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis

Hepatology
MedicineHepatology
2015English

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis

Scientifica
AgriculturalEnvironmental ScienceBiological Sciences
2012English

Hepatocellular Carcinoma and Direct-Acting Antivirals: A Never Ending Story?

Liver International
Hepatology
2017English

Letter: Direct-Acting Anti-Viral (DAA) Therapy Needs Strong Safety and Efficacy Check

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

The Majority of Hepatitis C Patients Treated With Direct Acting Antivirals Are at Risk for Relevant Drug-Drug Interactions

United European Gastroenterology Journal
OncologyGastroenterology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy